[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-01

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

\[F-18\] Fluorothymidine PET imaging will be used to create a radiation therapy treatment plan to avoid active bone marrow in the pelvis. This will be done to evaluate if sparing bone marrow will help maintain blood counts. This would impact chemotherapy administration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FLT PET Imaging for Cervical Cancer

NCT01075412

Uterine Cervical Neoplasms

TERMINATED PHASE2

[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers

NCT02108457

Gynecologic Cancer

COMPLETED

F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients

NCT00721799

Mouth Neoplasms Oropharyngeal Neoplasms Laryngeal Neoplasms +1 more

COMPLETED PHASE2

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

NCT00935090

Brain and Central Nervous System Tumors Chronic Myeloproliferative Disorders Leukemia +6 more

RECRUITING

Study to Calculate the Radiation Dosimetry in Subjects With Head and Neck Cancer

NCT00245349

Head and Neck Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Overall survival of pelvic cancer patients depends on control of systemic disease. If local radiation therapy depletes bone marrow function to such an extent that systemic therapies must be withheld, chances of metastatic failure increase significantly. This may be more significant for this group of patients because approximately one third of adult bone marrow is located in the pelvic region. Strategies to minimize toxicities would benefit a range of pelvic cancer patients including gynecologic, anal, rectal, and prostate. New chemoradiation combinations improve outcomes for these disease sites, but come at the cost of higher levels of toxicity. As many as 40% of cervical cancer patients miss at least one chemotherapy cycle due to hematologic toxicity and 36% of anal cancer patients experience grade 3 or 4 hematologic toxicity when undergoing chemoradiation therapy. A clinical trial of concurrent chemoradiation therapy for rectal cancer was terminated due to toxicity, including hematologic toxicities. Concurrent chemoradiation therapy shows promise for advanced stage prostate cancers, but it also increases grade 3 and 4 toxicities. To successfully limit hematologic toxicities for pelvic cancers, it is extremely advantageous to avoid irradiating the highly proliferative compartments of the pelvic bone marrow. However, the complex structure of the pelvis makes it difficult to assess the efficacy of radiation therapy (RT) planning strategies to avoid areas critical to hematopoiesis. Uptake of \[18F\]fluorothymidine imaged with positron emission tomography (FLT PET/CT) can be an accurate and sensitive tool for identifying and monitoring the effects of chemoradiation on proliferative pelvic bone marrow. Clinically validating the utility of FLT PET/CT imaging for identifying active bone marrow in the design of bone marrow sparing RT-plans and the important bone marrow assessment time points would provide a method to reduce acute and chronic hematologic toxicities for pelvic cancer patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Cervical Neoplasms Endometrial Neoplasms Anus Neoplasms Rectal Neoplasms Prostatic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fluorothymidine F 18 PET/CT

Fluorothymidine F 18 (FLT) PET/CT imaging ordered pre-radiation therapy, during weeks 1 and 2 of radiation therapy, and then at 1 month and 12 months after radiation therapy. The FLT PET/CT imaging ordered pre-radiation therapy is used for bone marrow sparing IMRT radiation therapy.

Group Type EXPERIMENTAL

fluorothymidine F 18

Intervention Type DRUG

A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fluorothymidine F 18

A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

[F-18] Fluorothymidine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability to understand and willingness to sign a written informed consent document.
* Recommended to undergo pelvic irradiation with concurrent chemotherapy.
* At least 18 years of age. Pediatrics would be best served by a protocol designed for their specific needs.
* Karnofsky Performance Status of at least 60% at time of screening.
* Life expectancy of greater than 6 months.
* Subject must have normal organ and marrow function (as defined below) within 30 days of study enrollment:

* leukocytes at least 3,000 / µL
* absolute neutrophil count of at least 1500 / µL
* platelets of at least 100,000 / µL
* creatinine equal to or less than the upper limit of normal
* not pregnant (as applicable)

Exclusion Criteria

* history of allergic reactions attributed to compounds of similar chemical or biologic composition to FLT
* an oncology research protocol requiring full pelvic radiation (i.e., 4 field box technique)
* uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* subjects taking nucleoside analog medications such as those used as antiretroviral agents.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No